



MAYNE PHARMA FURTHER STRENGTHENS BOARD WITH NEW DIRECTOR

28 June 2018, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr Patrick Blake has been appointed to the Board of Mayne Pharma Group Limited, effective immediately.

Mr Blake, a US resident, brings more than 30 years of global healthcare industry experience including more than 20 years at McKesson Corporation, one of the largest healthcare services and information technology companies globally, and more than 10 years at Baxter Healthcare Corporation.

Most recently, he was Executive Vice President of McKesson Corporation and Group President of McKesson Technology Solutions which serves the health IT needs of hospitals and health systems, payers, physicians, homecare agencies, retail pharmacies and manufacturers, a position he held from 2009 until 2017.

Previously, he was President of McKesson Specialty Health, a business focused on the US specialty/biotech sector which was McKesson's fastest growing business for three years during his leadership. He was also President of Customer Operations for McKesson Pharmaceutical (US) from 2000 to 2006, leading commercial sales and operations for the wholesale distribution of branded, specialty and generic pharmaceuticals and other related products.

Mayne Pharma Chairman, Mr Roger Corbett, AO said "I am extremely pleased that Pat Blake has accepted the appointment to the Mayne Pharma Board. Pat has a distinguished track record of success in growing profitable, complex and diverse businesses across multiple markets and channels. Pat's experience includes expertise in operations, marketing, technology, mergers and acquisition, strategy and restructuring, among others. His time at McKesson, one of the top three pharmaceutical wholesalers in the US, will be tremendously valuable in further strengthening our generic and specialty brand businesses."

"As Mayne Pharma continues to evolve, we believe Pat represents another outstanding addition to the Board. The Directors welcome Pat to the Board and we are confident that Mayne Pharma will greatly benefit from his experience, expertise and leadership."

Mr Blake has an MBA from Graziadio School of Business and Management at Pepperdine University and a Bachelor's degree in Economics from Denison University in Granville, Ohio.

For further information contact:

Lisa Pendlebury +61 3 8614 7777, lisa.pendlebury@maynepharma.com



ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including potent compounds, controlled substances, modified-release products and inherently unstable compounds.